Biopharma Patentees Must Navigate Inherent Obviousness
This year, the U.S. Court of Appeals for the Federal Circuit denied rehearing en banc in two appeals involving inherent obviousness — Persion Pharmaceuticals LLC v. Alvogen Malta Operations Ltd.[1] and...To view the full article, register now.
Already a subscriber? Click here to view full article